However, the impact of TAL1 on T‐ALL prognosis is still debatable as other studies report better outcome for TAL1 expressing T‐ALL.51 The higher expression of mTOR signaling pathway in CIMP− subgroup can also be speculated to contribute to the worse prognosis of this particular group since previous studies have shown the association of activated mTOR pathway with poor clinical outcome,52, 53 owing to the role of PI3K/Akt/mTOR pathway in the survival of drug‐resistant leukemia‐initiating cells.54 The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.